Kornimate/medical-research-clean huggingface dataset:
narcoms registry: a multiple sclerosis registry

Conditions: Multiple Sclerosis

Summary: this project is based on the idea that we can learn about the complexities of ms by following disease and treatment patterns in a large group of people over several years. the information gathered is used for research only. results are presented in summary form only. all details submitted by registry participants is strictly confidential. to participate in narcoms complete the baseline enrollment survey online through www.narcoms.org (or directly using the following link: https://redcap.link/py2rnyyn) or you can request a mail-in survey be sent to you by emailing msregistry@narcoms.org. you will be asked to update your information, online or by mail, twice a year. each update survey typically takes less than 20 minutes to complete. there is no cost to participate. for your participation you are offered a free subscription to the narcoms quarterly magazine, narcoms now. narcoms now provides a reliable source of information about the latest in ms research and disease management. you can stop participating in the registry at any time. you may also receive additional surveys or information on clinical trials. you are not obligated to participate and these additional studies will always come directly from narcoms. your contact information will not be shared or sold to other parties.

the data coordinating center, located at the university of texas southwestern medical center, maintains narcoms, the worlds largest voluntary, patient driven ms registry. the registry involves personnel from at least three other sites in the us and canada (cleveland clinic foundation, university of alabama at birmingham, and the dalhousie university in canada). over the past 20 years more than 41,000 people with ms across the u.s., canada and over 50 other countries, including over 4,000 veterans, have participated in the registry by submitting their health-related data by mail or online. registry data have been featured in over 100 peer-reviewed journal articles, scientific posters and presentations. these reports have provided information to guide new research. they also provide evidence supporting the approval of new drugs in the fight against ms. the north american research committee on multiple sclerosis (narcoms) is supported in part by the consortium of multiple sclerosis centers (cmsc), a not-for-profit professional organization for multiple sclerosis (ms) healthcare providers and researchers involving 198 participating centers of the ms treatment and research community.

Eligibility criteria:
inclusion criteria: * any individual who has been diagnosed with multiple sclerosis or clinically isolated syndrome * must be at least 18 years of age exclusion criteria: * none

Keywords: multiple sclerosis narcoms patient registry registry
virtual reality and spinal stimulation to improve arm function

Conditions: Tetraplegia

Summary: the main objective of our work is to develop and test the safety and feasibility of a home-based upper limb rehabilitation program for individuals with tetraplegia. the program will consist of simultaneous non-invasive spinal cord stimulation and immersive virtual exercises of the upper limbs, with a focus on shoulder and elbow function.


Eligibility criteria:
inclusion criteria: 1. incomplete low tetraplegia (c5-8; \[asia\] classification b-d), 2. free of contraindications to transspinal stimulation, 3. more than one-year post-injury, 4. stable medication regimen for the past month, 5. utilization of wheelchair as a primary mode of mobility (\>75% of the time). - exclusion criteria: 1. neurologic injury other than spinal cord injury 2. severe medical illness.

Keywords: upper limb function virtual reality spinal cord stimulation
a dose escalation study of sdx-7320 in patients with advanced refractory or late-stage solid tumors

Conditions: Advanced Malignancy; Advanced Solid Tumors; Neoplasm; Metastasis

Summary: this is a phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered sdx-7320 in patients with advanced refractory or late-stage solid tumors.

this is a phase 1 dose escalation study to assess the safety and tolerability of subcutaneously administered sdx-7320 in patients with advanced refractory or late-stage solid tumors. once the mtd has been determined up to 12 patients will be treated at this dose level, to further characterize treatment emergent adverse events (teaes).

Eligibility criteria:
inclusion criteria: * patients have at least one site of radiographically measurable disease. * eastern cooperative oncology group (ecog) status ≤1. * adequate renal and liver functions. * life expectancy ≥3 months. exclusion criteria: * patients that have undergone organ transplant surgery. * the patient has a known history of hepatitis a, b, or c and is on active anti-viral therapy. * history of gastric bypass surgery or banding procedure. * uncontrolled or refractory hypertension: systolic \>180 or diastolic \>110, or hypotension: systolic \<90 or diastolic \<50 despite medical treatment. * participation in any other trial of an investigational agent within 30 days prior to first dose of study drug. * the resting 12-lead electrocardiogram obtained during screening shows qtc (fridericia correction) ≥470 ms or has a congenital prolonged qt syndrome.

Keywords: cancer oncology solid tumors phase 1 sdx-7320 syndevrx metap2 breast post menopausal colorectal pancreatic ovarian endometrial esophageal lung renal prostate liver
exoskeleton variability optimization

Conditions: Peripheral Arterial Disease

Summary: the investigators will evaluate a potentially faster and more clinically feasible method to optimize exoskeletons in pilot tests in healthy in preparation for patients with peripheral artery disease.

this study will test different methods for optimizing exoskeletons. it will consist of an habituation session to the hip exoskeleton, an optimization session to find the optimal actuation settings using an algorithm that converges toward the optimum based on real-time measurements (human-inthe-loop algorithm) and a post-test at the end of optimization session to compare different conditions. the outcomes will be evaluated by surface electromyography (delsys), exoskeleton sensors (futek), ground reaction force (bertec treadmill), walking speed (bertec treadmill), indirect calorimetry (cosmed), and motion capture (vicon).

Eligibility criteria:
inclusion criteria: * ability to provide written consent * chronic claudication history * ankle-brachial index \< 0.90 at rest * stable blood pressure, lipides, and diabetes for \> 6 weeks * ability to walk on a treadmill for multiple five-minute spans. * ability to fit in exoskeleton: waist circumference 78 to 92 centimeters, thigh circumference 48 to 60 centimeters, minimal thigh length 28 centimeters. exclusion criteria: * rest pain or tissue loss due to peripheral artery disease (fontaine stage iii and iv). * foot ulceration. * acute lower extremity event secondary to thromboembolic disease or acute trauma * walking capacity limited by diseases which are unrelated to peripheral artery disease such as: neurological disorders, musculoskeletal disorders (arthritis, scoliosis, stroke, spinal injury, etc.), a history of ankle instability, knee injury, diagnosed joint laxity, lower limb injury, surgery within the past 12 months, joint replacement, pulmonary disease or breathing disorders, cardiovascular disease, or vestibular disorder. this will be determined by verbal questioning from research personnel by verbally asking about conditions limiting their walking, whether subjects are taking medications for those conditions, and physicians' recommendations about limiting activity. * acute injury or pain in their lower extremity or current illness. * inability to follow visual cues due to blindness. * inability to follow auditory cues due to deafness. * women who are currently pregnant are excluded for safety reasons.

Keywords: exoskeleton
a registry study on genetics and biomarkers of acute coronary syndrome

Conditions: Coronary Artery Disease; Acute Coronary Syndrome; Acute Myocardial Infarction; Unstable Angina

Summary: this is a national registry study to determine genetics risk factors and serial biomarkers of acute coronary syndrome.


Eligibility criteria:
acs case inclusion criteria: * written informed consent has been provided. * contact order form has been provided. * aged 18 years or older. * hospitalized within 48 hours of onset of symptoms. * diagnosis of stemi, nstemi or ua using the following definitions: 1.criteria for stemi diagnosis: 1. history of chest pain/discomfort and 2. persistent st-segment elevation (\> 30 min) of ≥ 0.1 mv in 2 or more contiguous ecg leads or presumed new left bundle branch block (lbbb) on admission and 3. elevation of cardiac biomarkers (ck-mb, troponins): at least one value above the 99th percentile of the local laboratory upper reference limit. 2.criteria for nstemi diagnosis: 1.history of chest pain/discomfort and 2.lack of persistent st-segment elevation, lbbb or intraventricular conduction disturbances and 3.elevation of cardiac biomarkers (ck-mb, troponins): at least one value above the 99th percentile of the local laboratory upper reference limit. 3.criteria for unstable angina diagnosis: 1. symptoms of angina at rest or on minimal exercise and 2. at least 0.5mm st deviation in at least 2 leads and 3. no increase in biomarkers of necrosis 4. or objective evidence of ischaemia by non-invasive imaging or significant coronary stenosis as determined by the treating physician at angiography if this is standard practice in study site. case exclusion criteria: patients will not be eligible to participate if any of the following exclusion criteria are present: * ua, stemi and nstemi precipitated by or as a complication of surgery, trauma, or gi bleeding or post-pci. * ua, stemi and nstemi occurring in patients already hospitalized for other reasons. * presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances). * presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy. * current participation in a randomised interventional clinical trial. control inclusion criteria: * age and gender are matched with cases. * no coronary artery disease was detected by coronary ct examination. * normal biochemical indicators.
a study to evaluate the pharmacokinetics and the safety after administration of "br1015" and co-administration of "br1015-1" and "br1015-2" under fed conditions in healthy volunteers

Conditions: Hypertension

Summary: the purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "br1015" and co-administration of "br1015-1" and "br1015-2" under fed conditions in healthy volunteers


Eligibility criteria:
inclusion criteria: * those who weigh 50 kg or more and have body mass index (bmi) within the range of 18.0 to 30.0kg/m2 at screening visit. * those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the investigational products, expected adverse events, etc. * those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using methods of contraception accepted in clinical trial\* from the date of the first administration of the investigational products to 14 days after the last administration and disagrees to provide their sperm or ovum. * methods of contraception accepted in clinical trial: combined use of intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used. exclusion criteria: * those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days prior to the first day of administration or have taken drugs concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as interaction of investigational products, half-life of concomitant drugs) * those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months prior to the first administration date.(however, the termination for participation in other clinical trials are based on the last administration date of their investigational products) * those who have a medical history of gastrointestinal surgery or gastrointestinal diseases that may affect the absorption of drugs. (except for simple appendectomy, hernia surgery) * in the case of a female subject, those suspected pregnancy, pregnant woman, lactating woman.
renal denervation hypertension after stroke

Conditions: Stroke; Hypertension

Summary: it is known, that hypertension is the major risk factor of stroke and recurrent stroke. blood pressure reduction - together with antithrombotics - remain crucial in stroke prevention. this pilot study will examine the effect of renal nerve denervation in patients with treatment resistant hypertension after ischemic stroke or dwi/dti-verified stroke. with 24 hours blood pressure measurements the effect after renal nerve denervation is examined 1,3,6 and 12 months after the procedure.

radio frequent ablation is used to renal nerve denervation (rnd) and is a new invasive method used in treatment for hypertensive patients, where the sympathetic nerves to the kidneys ablates. rnd shows a significant reduction in the systolic and diastolic blood pressure in patients with treatment resistant hypertension. the hypothesis is that rdn is able to reduce the blood pressure in patients with previous stroke and treatment resistant hypertension and thereby reduce the risk of a new stroke. aim of study: 1. to validate the reduction in blood pressure after rnd in patients with stroke and treatment resistant hypertension compared to the results achieved in patients only with essential hypertension 2. to examine if this treatment is possible on patients after stroke (procedure related limitations and security of the patient) 3. to describe the effect of rnd in the development of changes in the white matter over time

Eligibility criteria:
inclusion criteria: * 18+ years old * clinical verified stroke within the last year * treatment resistant hypertension at 150 mm hg or higher systolic at consultation * modified ranking between 0-2 exclusion criteria: * lack of informed consent * renal artery anatomy, which prevents the procedure * reno vascular disease * pacemaker * haemodynamic vascular occlusion or valve disease * pregnancy or women in the childbearing age * secondary hypertension * mean systolic blood pressure over 180 mm hg

Keywords: renal nerve denervation
influence of gender difference on knee proprioception in non-specific low back pain among young adults

Conditions: Non-Specific Chronic Low-back Pain

Summary: the aim of the study is to investigate the impact of gender difference on knee proprioception among non specific low back pain young adults.

low back pain (lbp) is one of the most common musculoskeletal disorders and the leading causes of disability and work absence globally. lbp notonly causes individual suffering, but also a heavy burden to the society. despite this, up to 85% patients with lbp cannot be clearly diagnosed and are classified as non-specific lbp (nslbp). proprioception plays an important role in the planning of precise and coordinated movements, in maintaining balance and controlling body posture. it also exerts its influence on motor learning and re-education. proprioception deficit has been identified in people with lbp and it has been suggested that these deficits might be associated with causes and mechanisms of lbp. although the local investigation of proprioception is important, the proprioceptive deficits due to lbp may not be restricted only to the lumbar region. anatomical and biomechanical associations between the knee and lower back segments imply that the knee might be adversely affected in patients with lbp. there is a gap in the literature concerning sex differences in the knee joint proprioception. although biomechanical and hormonal differences between males and females are suspected to be responsible for increasing this incidence.

Eligibility criteria:
inclusion criteria: 1. forty-one patients from each gender participated in the study. 2. subject's age ranged from 18-26 years old, with body mass index (bmi) less than 30kg/m2 3. the dominant knees of the subjects (defined as the leg used for kicking) are tested. 4. pain between three and eight using numerical pain rating scale nprs, and oswestry disability index score less than 20. 5. all the subjects sign an informed consent form. 6. able to comprehend and follow the examiner's instructions. exclusion criteria: 1. limitation of active and passive knee joint motion. 2. clinical signs of an impairment or abnormality in the knee (such as abnormal range of motion, muscle weakness, or malalignment). 3. injury to the knee that required medical attention. 4. current pain in the knee or previous surgery on the knee. 5. not able to understand and follow the commands of the examiner.

Keywords: gender difference knee proprioception chronic non-specific low-back pain
increasing physical activity among overweight women with mobility disabilities.

Conditions: Obesity

Summary: this study aims to increase physical activity among overweight african-american women with mobility limitations.

regular, sustainable physical activity can have a dramatic effect on reducing obesity and other secondary conditions and increasing quality of life. people with mobility limitations have a higher level of physical inactivity resulting from numerous personal and environmental barriers to physical activity participation. this project will evaluate the feasibility of increasing physical activity among overweight individuals with mobility limitations through physician-referrals to a personalized exercise programme at the chicago-based national center on physical activity and disability (ncpad).

Eligibility criteria:
inclusion criteria: * 18 years or older * english speaking * self-reported mobility limitation * bmi greater than or equal to 27 * receiving care at the university of illinois, chicago (uic) medical center * sedentary exclusion criteria: * did not receive physician approval to participate

Keywords: obesity, mobility limitations, women, physical activity
study of transcranial direct current stimulation to treat epilepsy

Conditions: Focal Epilepsy; Generalized Onset Epilepsy; Sleep-related Epileptic Encephalopathy

Summary: the purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tdcs) can reduce the number and intensity of epileptic seizures.

tdcs for treatment of epilepsy has been studied previously with results suggesting that it can lead to a notable seizure reduction for a limited time period after the cessation of stimulation, e.g., about one month. here, we assess further aspects of tdcs treatment protocols, including the feasibility and safety of at-home use.

Eligibility criteria:
inclusion criteria * clinical diagnosis of generalized onset or focal epilepsy or sleep-related epileptic encephalopathy. * estimated to have at least 2 countable seizures per month or spike-wave index ≥50%. * has not had control with at least 2 anti-seizure medicines. * able to maintain a constant medication for duration of the study (rescue meds allowed). * subject or legally authorized representative is able to understand consent and keep a seizure diary in english. exclusion criteria: * a disease likely to progress over course of the study. * psychogenic non-epileptic seizures. * suicide attempt or psychiatric hospitalization past 2 years. * a skin condition interfering with scalp electrodes or allergy to silver. * women will verify not pregnant, and if applicable, have a serum pregnancy test. * implanted devices (e.g. pacemakers)-except vns, which is allowed.
vaginal cleaning using povidone iodine before cs to reduce postoperative wound infection

Conditions: Cesarean Section Complications; Vaginal Infection; Postoperative Infection

Summary: the aim of work to assess the effectiveness of preoperative vaginal cleansing with povidone iodine on reduction of post caesarean section wound infection research questions: does vaginal cleaning using povidone iodine before cesarean section has effect on reduction of postoperative wound infection??


Eligibility criteria:
inclusion criteria: * 1. pregnant women who are 37 weeks gestation or more scheduled for elective cesarean section or those in labor with a limited number of vaginal examinations less than 5 times preoperatively. 2. pregnant women who are 37 weeks gestation or more with rupture of membranes but duration less than 24 hours 3. women consenting to be included in the study. exclusion criteria: 1. abnormally invasive placenta and placenta previa. 2. intra-partum fever. 3. prolonged rupture of membranes more than 24 hours 4. history of exposure to radiation treatment for cancer. 5. history of gynecological infections (pid). 6. history of abdominal infections, e.g., peritonitis. 7. debilitating diseases like diabetes mellitus, thyroid disorders, cushing disease, abdominal malignancy. 8. obesity is defined as pregnant bmi \>30 kg/m2. 9. history of wound infection or burst abdomen. 10. history suggestive of massive bleeding during previous cesarean section. 11. allergy to iodine-containing solutions 12. pregnant women with severe anemia defined as hb \<7 g/dl. 13. cases with intra-abdominal drain deployment are discarded. 14. obstructed labor with numerous vaginal examinations.